P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
364 Indexcentral nervous system (CNS)
drugs affecting, 270 –281
anticonvulsants, 279 –281
antidepressants, 274 –278
anxiolytics, 270 –274
hypnotics, 270 –274
physiology, 270
central venous access, 8
centrally acting drugs, 265 –268
cephalosporins, 315 –316
first-generation, 316
mechanism of action, 315
pharmacokinetics, 315 –316
protein binding, 315 –316
side effects, 316
third-generation, 316
use during CVVHDF, 316
cephradine, 315 –316
second-generation, 316
cephuroxime, 315 –316
cGMP, 30
chelating agents, 24 , 41
chemoreceptor trigger zone, 282
children
propofol contraindication,110t
see alsoinfants; neonates
chiral centres,47f
more than one, 48
single, 47 –48
chloride ion(s)
loop diuretics reabsorption inhibition, 307
reabsorption inhibition by thiazides, 305
chloride ion channels, ligand-gated, 270
chlorothiazide, 305 –307
chlorpromazine, 283 –284
effects, 284
kinetics, 284
mechanism of action, 284
uses, 283
chlorpropamide, 348 –349
side-effects, 349
choline, 175
choline group, 94
cholinesterase
neonates, 23
plasma
genetic variants,184t
inhibition, 183 –184
mivacurium metabolism, 192
suxamethonium metabolism, 18 –19
variants, 19
cilastatin, imipenem combination, 317
cimetidine, 41 –42, 293–294, 349
ciprofloxacin, 320 –321
circus mechanisms, 229cis-atracurium, 18 , 189–190
clarithromycin, 318 –319
clavulanic acid, 313 –314
clearance of drug, 64 –67, 71, 73–74
constant relationships, 75
inter-compartmental rates, 74
rate constant,66f
volume of distribution, 72 –73
clindamycin, 323 –324
clonidine, 266 –267
effects, 266 –267
kinetics, 267
mechanism of action, 266
presentation, 266
uses, 266
clopidogrel, 337 –338
clotting factors, 335 –336, 342
unfractionated heparin mechanism
of action, 340
warfarin therapy, 342 –343
coagulation
amplification, 336
cascade, 335 –336, 336f
cell-based model, 336
classical model, 335 –336
initiation, 336
physiology, 335 –336
propagation, 336
coagulation, drugs affecting, 335 –346
antiplatelet drugs, 337 –339
fibrinolytic system, 344 –346
oral anticoagulants, 342 –344
cocaine,173t
codeine, 91 , 143
papaveretum, 142 –143
poor metabolizers, 143
colloids, 300 , 304t
compartmental models, 50 –59, 63–64,
65f, 71
concentration effect,119f
concentration gradient, 5
concentration of drug, 50 –51, 64–67
plasma, 50 –52
differentiation, 61 –62
dose required, 75 –76
natural logarithms, 58 –59
repeated dose, 75 –76
concentration–time curve, 71
Conn’s syndrome, 308 –309
constants, relationships, 75
context sensitive half-time, 77 –78, 78f, 80–81
remifentanil, 81
continuous veno-venous haemodiafiltration
(CVVHDF)
acyclovir use during, 333 –334